Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531530 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01531530 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 26 participants.
The verdict
NCT01531530, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
Interventions
- OTHER Placebo
- BIOLOGICAL CVD 1208S, a Shigella flexneri 2a live, oral vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531530
The ClinicalTrials.gov registry entry for NCT01531530 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01531530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531530 about?
NCT01531530 is a clinical study titled "Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP". The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
What is the current status of trial NCT01531530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01531530?
The interventions under investigation include: Placebo (OTHER), CVD 1208S, a Shigella flexneri 2a live, oral vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01531530?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.